The role of HDACs inhibitors in childhood and adolescence acute leukemias

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Masetti, Riccardo ^a   Serravalle, Salvatore ^a   Biagi, Carlotta ^a   Pession, Andrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; AZACITIDINE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DEPSIPEPTIDE; DOCETAXEL; ENTINOSTAT; ETOPOSIDE; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IDARUBICIN; METHOTREXATE; MOCETINOSTAT; PANOBINOSTAT; PHOSPHOTRANSFERASE INHIBITOR; PIVALOYLOXYMETHYL BUTYRATE; RETINOIC ACID; ROMIDEPSIN; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENCE; ADOLESCENT; ANOREXIA; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HYPOKALEMIA; INFECTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROTOXICITY; NONHUMAN; POLYCYTHEMIA VERA; PROSTATE TUMOR; PROTEIN FUNCTION; REVIEW; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG SCREENING; ENZYMOLOGY; LEUKEMIA; METABOLISM;

ADOLESCENT; ANIMALS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA;

EID: 79952229923     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/148046     Document Type: Review

References (73)

1. Ravindranath Y., Recent advances in pediatric acute lymphoblastic and myeloid leukemia Cur (Pubitemid 36135644)
2. Pui C. H., Schrappe M., Ribeiro R. C., Niemeyer C. M., Childhood and adolescent lymphoid and myeloid leukemia American Society of Hematology. Education Program 2004 118 145
3. Conter V., Aric M., Basso G., Biondi A., Barisone E., Messina C., Parasole R., De Rossi G., Locatelli F., Pession A., Santoro N., Micalizzi C., Citterio M., Rizzari C., Silvestri D., Rondelli R., Nigro L. L., Ziino O., Testi A. M., Masera G., Valsecchi M. G., Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia Leukemia 2010 24 2 255 264
4. Aric M., Valsecchi M. G., Rizzari C., Barisone E., Biondi A., Casale F., Locatelli F., Lo Nigro L., Luciani M., Messina C., Micalizzi C., Parasole R., Pession A., Santoro N., Testi A. M., Silvestri D., Basso G., Masera G., Conter V., Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster-based chemotherapy Journal of Clinical Oncology 2008 26 2 283 289
5. Pession A., Rondelli R., Basso G., Rizzari C., Testi A. M., Fagioli F., De Stefano P., Locatelli F., Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols Leukemia 2005 19 12 2043 2053 (Pubitemid 41741596)
6. Tallen G., Ratei R., Mann G., Kaspers G., Niggli F., Karachunsky A., Ebell W., Escherich G., Schrappe M., Klingebiel T., Fengler R., Henze G., von Stackelberg A., Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90 Journal of Clinical Oncology 2010 28 14 2339 2347
7. Abrahamsson J., Clausen N., Gustafsson G., Hovi L., Jonmundsson G., Zeller B., Forestier E., Heldrup J., Hasle H., Improved outcome after relapse in children with acute myeloid leukaemia British Journal of Haematology 2007 136 2 229 236 (Pubitemid 46020750)
8. Kaspers G. J. L., Zwaan C. N., Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica 2007 92 11 1519 1532 (Pubitemid 350144128)
9. Brown P., Hunger S. P., Smith F. O., Carroll W. L., Reaman G. H., Novel targeted drug therapies for the treatment of childhood acute leukemia Expert Review of Hematology 2009 2 2 145 158
10. Oki Y., Issa J. P., Review: recent clinical trials in epigenetic therapy Reviews on Recent Clinical Trials 2006 1 2 169 182
11. Kouraklis G., Theocharis S., Histone deacetylase inhibitors and anticancer therapy Current Medicinal Chemistry 2002 2 4 477 484 (Pubitemid 34649886)
12. Timmermann S., Lehrmann H., Polesskaya A., Harel-Bellan A., Histone acetylation and disease Cellular and Molecular Life Sciences 2001 58 5-6 728 736 (Pubitemid 32553030)
13. Marks P. A., Xu W. S., Histone deacetylase inhibitors: potential in cancer therapy Journal of Cellular Biochemistry 2009 107 4 600 608
14. Glozak M. A., Seto E., Histone deacetylases and cancer Oncogene 2007 26 37 5420 5432 (Pubitemid 47255924)
15. Warrell R. P. Jr., He L. Z., Richon V., Calleja E., Pandolfi P. P., Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase Journal of the National Cancer Institute 1998 90 21 1621 1625 (Pubitemid 28523436)
16. Lin R. J., Nagy L., Inoue S., Shao W., Miller W. H., Evans R. M., Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 1998 391 6669 811 814 (Pubitemid 28099682)
17. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F. F., Zamir I., Seiser C., Grignani F., Lazar M. A., Minucci S., Pelicci P. G., Fusion proteins of the retinoic acid receptor- recruit histone deacetylase in promyelocytic leukaemia Nature 1998 391 6669 815 818 (Pubitemid 28099683)
18. Klisovic M. I., Maghraby E. A., Parthun M. R., Guimond M., Sklenar A. R., Whitman S. P., Chan K. K., Murphy T., Anon J., Archer K. J., Rush L. J., Plass C., Grever M. R., Byrd J. C., Marcucci G., Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells Leukemia 2003 17 2 350 358 (Pubitemid 36266913)
19. Liu S., Klisovic R. B., Vukosavljevic T., Yu J., Paschka P., Huynh L., Pang J., Neviani P., Liu Z., Blum W., Chan K. K., Perrotti D., Marcucci G., Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells Journal of Pharmacology and Experimental Therapeutics 2007 321 3 953 960 (Pubitemid 46762689)
20. Dorrance A. M., Liu S., Yuan W., Becknell B., Arnoczky K. J., Guimond M., Strout M. P., Feng L., Nakamura T., Yu LI., Rush L. J., Weinstein M., Leone G., Wu L., Ferketich A., Whitman S. P., Marcucci G., Caligiuri M. A., Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations Journal of Clinical Investigation 2006 116 10 2707 2716 (Pubitemid 44511634)
21. Paris M., Porcelloni M., Binaschi M., Fattori D., Histone deacetylase inhibitors: from bench to clinic Journal of Medicinal Chemistry 2008 51 6 1505 1529 (Pubitemid 351438836)
22. Al-Janadi A., Chandana S. R., Conley B. A., Histone deacetylation: an attractive target for cancer therapy? Drugs in R and D 2008 9 6 369 383
23. Abujamra A. L., dos Santos M. P., Roesler R., Schwartsmann G., Brunetto A. L., Histone deacetylase inhibitors: a new perspective for the treatment of leukemia Leukemia Research 2010 34 6 687 695
24. Gore S. D., Baylin S., Sugar E., Carraway H., Miller C. B., Carducci M., Grever M., Galm O., Dauses T., Karp J. E., Rudek M. A., Zhao M., Smith B. D., Manning J., Jiemjit A., Dover G., Mays A., Zwiebel J., Murgo A., Weng L. J., Herman J. G., Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Research 2006 66 12 6361 6369
25. Garcia-Manero G., Kantarjian H. M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., Rytting M., Wierda W. G., Ravandi F., Koller C., Xiao L., Faderl S., Estrov Z., Cortes J., O'Brien S., Estey E., Bueso-Ramos C., Fiorentino J., Jabbour E., Issa J. P., Phase 1/2 study of the combination of 5-aza- 2′ -deoxycytidine with valproic acid in patients with leukemia Blood 2006 108 10 3271 3279
26. Richon V. M., Garcia-Vargas J., Hardwick J. S., Development of vorinostat: current applications and future perspectives for cancer therapy Cancer Letters 2009 280 2 201 210
27. Butler L. M., Agus D. B., Scher H. I., Higgins B., Rose A., Cordon-Cardo C., Thaler H. T., Rifkind R. A., Marks P. A., Richon V. M., Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Research 2000 60 18 5165 5170
28. Batty N., Malouf G. G., Issa J. P. J., Histone deacetylase inhibitors as anti-neoplastic agents Cancer Letters 2009 280 2 192 200
29. Vrana J. A., Decker R. H., Johnson C. R., Wang Z., Jarvis W. D., Richon V. M., Ehinger M., Fisher P. B., Grant S., Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-x(L), c-Jun, and p21(CIP1), but independent of p53 Oncogene 1999 18 50 7016 7025 (Pubitemid 30028872)
30. Einsiedel H. G., Kawan L., Eckert C., Witt O., Fichtner I., Henze G., Seeger K., Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia Leukemia 2006 20 8 1435 1436 (Pubitemid 44084058)
31. Leclerc G. J., Mou C., Leclerc G. M., Mian A. M., Barredo J. C., Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy Leukemia 2010 24 3 552 562
32. He L. Z., Tolentino T., Grayson P., Zhong S., Warrell R. P., Rifkind R. A., Marks P. A., Richon V. M., Pandolfi P. P., Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia Journal of Clinical Investigation 2001 108 9 1321 1330 (Pubitemid 33107760)
33. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W. G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V. R., Randolph S. S., Hardwick J. S., Reilly J. F., Chen C., Ricker J. L., Secrist J. P., Richon V. M., Frankel S. R., Kantarjian H. M., Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood 2008 111 3 1060 1066 (Pubitemid 351213383)
34. Fouladi M., Park J. R., Stewart C. F., Gilbertson R. J., Schaiquevich P., Sun J., Reid J. M., Ames M. M., Speights R., Ingle A. M., Zwiebel J., Blaney S. M., Adamson P. C., Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report Journal of Clinical Oncology 2010 28 22 3623 3629
35. Burke M. J.,. Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment, http://clinicaltrials.gov/ct2/ show/NCT00882206?term=VORINOSTAT+AND+leukemiarank=6
36. Garcia-Manero G.,. Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), http://clinicaltrials.gov/ct2/show/NCT00656617?term= VORINOSTAT+AND+leukemiarank=20
37. Gttlicher M., Minucci S., Zhu P., Krmer O. H., Schimpf A., Giavara S., Sleeman J. P., Lo Coco F., Nervi C., Pelicci P. G., Heinzel T., Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO Journal 2002 20 24 6969 6978 (Pubitemid 34062289)
38. Krmer O. H., Zhu P., Ostendorff H. P., Golebiewski M., Tiefenbach J., Peters M. A., Brill B., Groner B., Bach I., Heinzel T., Gttlicher M., The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 EMBO Journal 2003 22 13 3411 3420 (Pubitemid 36834871)
39. Tonelli R., Sartini R., Fronza R., Freccero F., Franzoni M., Dongiovanni D., Ballarini M., Ferrari S., D'Apolito M., Di Cola G., Capranico G., Khobta A., Campanini R., Paolucci P., Minucci S., Pession A., G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent Leukemia 2006 20 7 1307 1310 (Pubitemid 43905841)
40. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., Altucci L., Nervi C., Minucci S., Pelicci P. G., Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nature Medicine 2005 11 1 71 76 (Pubitemid 40215840)
41. Siitonen T., Koistinen P., Savolainen E. R., Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27 in acute myeloblastic leukemia cells Leukemia Research 2005 29 11 1335 1342 (Pubitemid 41297646)
42. Sanchez-Gonzalez B., Yang H., Bueso-Ramos C., Hoshino K., Quintas-Cardama A., Richon V. M., Garcia-Manero G., Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor Blood 2006 108 4 1174 1182 (Pubitemid 44232012)
43. Yang H., Hoshino K., Sanchez-Gonzalez B., Kantarjian H., Garcia-Manero G., Antileukemia activity of the combination of 5-aza- 2′ -deoxycytidine with valproic acid Leukemia Research 2005 29 7 739 748 (Pubitemid 40779480)
44. Kuendgen A., Knipp S., Fox F., Strupp C., Hildebrandt B., Steidl C., Germing U., Haas R., Gattermann N., Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia Annals of Hematology, Supplement 2005 84 13, supplement 61 66
45. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K., Romanski A., Kramer O. H., Kampfmann M., Hoelzer D., Neubauer A., Ruthardt M., Ottmann O. G., Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia Cancer 2005 104 12 2717 2725 (Pubitemid 41798282)
46. Soriano A. O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., Cortes J., Wierda W. G., Ouzounian S., Quezada A., Pierce S., Estey E. H., Issa J. P. J., Kantarjian H. M., Garcia-Manero G., Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 2007 110 7 2302 2308 (Pubitemid 47523148)
47. Minucci S., Pelicci P. G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nature Reviews Cancer 2006 6 1 38 51 (Pubitemid 43054973)
48. Rosato R. R., Almenara J. A., Grant S., The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1 Cancer Research 2003 63 13 3637 3645 (Pubitemid 36793047)
49. Nishioka C., Ikezoe T., Yang J., Takeuchi S., Phillip Koeffler H., Yokoyama A., MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells Leukemia Research 2008 32 9 1382 1392
50. Nishioka C., Ikezoe T., Yang J., Koeffler H. P., Yokoyama A., Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells Leukemia 2008 22 12 2159 2168
51. Maggio S. C., Rosato R. R., Kramer L. B., Dai Y., Rahmani M., Paik D. S., Czarnik A. C., Payne S. G., Spiegel S., Grant S., The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells Cancer Research 2004 64 7 2590 2600 (Pubitemid 38523917)
52. Jaboin J., Wild J., Hamidi H., Khanna C., Kim C. J., Robey R., Bates S. E., Thiele C. J., MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors Cancer Research 2002 62 21 6108 6115 (Pubitemid 35244459)
53. Gojo I., Jiemjit A., Trepel J. B., Sparreboom A., Figg W. D., Rollins S., Tidwell M. L., Greer J., Eun J. C., Lee M. J., Gore S. D., Sausville E. A., Zwiebel J., Karp J. E., Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 2007 109 7 2781 2790 (Pubitemid 46482071)
54. Batova A., Shao L. E., Diccianni M. B., Yu A. L., Tanaka T., Rephaeli A., Nudelman A., Yu J., The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines Blood 2002 100 9 3319 3324 (Pubitemid 35217083)
55. Aviram A., Zimrah Y., Shaklai M., Nudelman A., Rephaeli A., Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line International Journal of Cancer 1994 56 6 906 909 (Pubitemid 24102761)
56. Kasukabe T., Rephaeli A., Honma Y., An anti-cancer derivative of butyric acid (pivalyloxymethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells British Journal of Cancer 1997 75 6 850 854 (Pubitemid 27110701)
57. A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemi, http://clinicaltrials.gov/ct2/show/NCT00083473?term=AN-9rank=1
58. A Pilot Study of Pivanex in Patients With Malignant Melanoma, http://clinicaltrials.gov/ct2/show/NCT00087477?term=AN-9rank=2
59. Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer, http://clinicaltrials.gov/ ct2/show/NCT00073385?term=AN-9rank=3
60. Guerini V., Barbui V., Spinelli O., Salvi A., Dellacasa C., Carobbio A., Introna M., Barbui T., Golay J., Rambaldi A., The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2 Leukemia 2008 22 4 740 747 (Pubitemid 351552623)
61. Rambaldi A., Dellacasa C. M., Finazzi G., Carobbio A., Ferrari M. L., Guglielmelli P., Gattoni E., Salmoiraghi S., Finazzi M. C., Di Tollo S., D'Urzo C., Vannucchi A. M., Barosi G., Barbui T., A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms British Journal of Haematology 2010 150 4 446 455
62. Rambaldi A.,. Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV), http://clinicaltrials.gov/ct2/show/ NCT00928707?term=NCT00928707rank=1
63. Barbetti V., Gozzini A., Rovida E., Morandi A., Spinelli E., Fossati G., Mascagni P., Lbbert M., Dello Sbarba P., Santini V., Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells Oncogene 2008 27 12 1767 1778 (Pubitemid 351380272)
64. Piekarz R. L., Frye R., Turner M., Wright J. J., Allen S. L., Kirschbaum M. H., Zain J., Prince H. M., Leonard J. P., Geskin L. J., Reeder C., Joske D., Figg W. D., Gardner E. R., Steinberg S. M., Jaffe E. S., Stetler-Stevenson M., Lade S., Fojo A. T., Bates S. E., Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma Journal of Clinical Oncology 2009 27 32 5410 5417
65. StatBite: FDA oncology drug product approvals in 2009 Journal of the National Cancer Institute 2010 102 4 219
66. Kosugi H., Ito M., Yamamoto Y., Towatari M., Ito M., Ueda R., Saito H., Naoe T., In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice Japanese Journal of Cancer Research 2001 92 5 529 536 (Pubitemid 32515094)
67. Byrd J. C., Marcucci G., Parthun M. R., Xiao J. J., Klisovic R. B., Moran M., Lin T. S., Liu S., Sklenar A. R., Davis M. E., Lucas D. M., Fischer B., Shank R., Tejaswi S. L., Binkley P., Wright J., Chan K. K., Grever M. R., A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood 2005 105 3 959 967 (Pubitemid 40170861)
68. Klimek V. M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., Panageas K., Wright J. J., Pandolfi P. P., Nimer S. D., Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (Romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes Clinical Cancer Research 2008 14 3 826 832 (Pubitemid 351231166)
69. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., Newsome W. M., Miller W. H., Rousseau C., Kalita A., Bonfils C., Dubay M., Patterson T. A., Li Z., Besterman J. M., Reid G., Laille E., Martell R. E., Minden M., Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 2008 112 4 981 989
70. Fournel M., Bonfils C., Hou Y., Yan P. T., Trachy-Bourget M. C., Kalita A., Liu J., Lu AI. H., Zhou N. Z., Robert M. F., Gillespie J., Wang J. J., Ste-Croix H., Rahil J., Lefebvre S., Moradei O., Delorme D., MacLeod A. R., Besterman J. M., Li Z., MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo Molecular Cancer Therapeutics 2008 7 4 759 768 (Pubitemid 351551029)
71. Lane A. A., Chabner B. A., Histone deacetylase inhibitors in cancer therapy Journal of Clinical Oncology 2009 27 32 5459 5468
72. Scuto A., Kirschbaum M., Kowolik C., Kretzner L., Juhasz A., Atadja P., Pullarkat V., Bhatia R., Forman S., Yen Y., Jove R., The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph acute lymphoblastic leukemia cells Blood 2008 111 10 5093 5100
73. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., Masson E., Rae P., Laird G., Sharma S., Kantarjian H., Dugan M., Albitar M., Bhalla K., A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clinical Cancer Research 2006 12 15 4628 4635 (Pubitemid 44297814